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used ICER and 2 used C/E as outcomes. Liraglutide is more cost-effective than 
sitagliptin because the ICER of liraglutide vs. sitagliptin is $25742/QALY in USA, 
£9851/QALY in England and EUR13266/QALY in Spain. All the reported ICERs were 
below the implemented country-specific thresholds. The results of 2 studies of 
exenatide vs. sitagliptin were opposite. CONCLUSIONS: Present published lit-
eratures showed GLP-1receptor agonist may be more cost-effective than DPP-4 
inhibitor. But the conclusions remain to be confirmed further by more high qual-
ity studies.
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OBJECTIVES: Develop a cost-utility assessment with diabetes mellitus type 2 
patients comparing detemir to glargine and NPH insulin in Colombia. METHODS: 
A Markov chain model was adapted to incorporate the quality life measures to 
the disease events, using the startup of NPH insulin, detemir or glargine to the 
development of macro and microvascular events or death, in a 5-year time horizon 
and for a 10.000 patients cohorts, with different levels of glycosylated hemoglobin. 
By the other hand, quality life data were derived from international research and 
used as utility measure in each event. Costs were estimated from the 2014 health 
system transactions values in Colombian pesos. Furthermore, additional parameters 
as the effectiveness information and hypoglycemic events were updated to 2014. 
The research included a Monte Carlo model for sensibility analysis and a budget 
impact analysis. RESULTS: Detemir taken at a standard daily dose of 20IU present 
less macro and microvascular events compare with other drugs. The QALYs aver-
age for determir harm were 2,60 to 2,54 using glargine and 2,53 using NPH insulin. 
The final average-cost of detemir was $ COP 88.720,67 less per patient tan glargine, 
and $ COP 75.252,50 less than NPH insulin. Detemir dominance remained through 
the probabilistic analysis. CONCLUSIONS: Under the analyzed conditions determir 
would be dominant compare to using NPH or glangine, from the QALYs viewpoint 
and in a 5-year time horizon.
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OBJECTIVES: To assess the prevalence of and predictors associated with genitou-
rinary (GU) conditions among patients with type 2 diabetes mellitus (T2DM) and 
to understand the treatment pathways patients employ when these conditions 
occur. METHODS: An internet-based survey was conducted in July 2014. The sam-
ple recruited from YouGov PollingPoint Panel in the U.S. included 2,000 adults with 
T2DM diagnosed by a physician for at least one year and treated with T2DM medica-
tions. Participants who reported a GU condition (urinary tract infection [UTI] and/or 
genital infection [GI] including genital yeast infection, bacterial vaginosis/vaginitis 
[BV], or balanitis) in the past 12 months were asked to complete survey questions 
about their GU conditions. Descriptive analysis and logistic regressions were per-
formed. RESULTS: 399 participants (20%) experienced at least one GU condition in 
the past 12 months; 309 (15.5%) reported UTI and 169 (8.5%) reported GI condition. 
The most common GI condition was yeast infection (n= 115, 5.8%). Predictors of GU 
conditions included: higher HbA1c level (i.e. 8%> HbA1c ≥ 7% vs. < 7%, OR [95% CI] 
= 1.41 [1.05, 1.90]), female vs. male (2.78 [2.16, 3.58]), and more comorbid conditions 
(i.e. 1 vs. > 5 comorbid conditions, 0.38 [0.23, 0.64]). Among respondents reporting 
GU conditions, 82.4% sought professional care. Female vs. male (2.00 [1.08, 3.70]), 
chronic vs. acute infections (2.83 [1.35, 5.94]), and more comorbid conditions (i.e. 1 
vs. > 5 comorbid conditions, 0.14 [0.04, 0.47]) were associated with higher odds of 
seeking professional care. CONCLUSIONS: In this study, 20% of participants with 
T2DM experienced GU conditions in the past 12 months, among whom 17.6% did 
not seek professional care. Predictors observed in this study could help physicians 
and health plans to identify those patients at high risk of GU conditions or those 
whose condition may potentially advance to professional care to better manage 
these conditions among the T2DM population.
DiaBetes/enDocrine DisorDers – Patient-reported outcomes & Patient 
Preference studies
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OBJECTIVES: To examine the effect of a pharmacist telephone intervention on pre-
venting medication discontinuation of ACE-Is/ARBs among non-adherent hyper-
tensive patients with diabetes enrolled in a Texas-based Medicare Advantage 
plan. METHODS: The health plan medical claims data was used to identify patients 
with hypertension and diabetes diagnoses and at least 2 fills for ACE-Is or ARBs 
between January/2013- October/2013. Patients who failed to refill their medication 
for more than one day, and had a proportion of days covered (PDC) < 0.8 were con-
sidered non-adherent and contacted by a pharmacist by phone. Multivariate logistic 
regression was conducted to assess the intervention effect on medication discontin-
uation during the 6 months post-intervention. The outcome variable was a categori-
cal variable of continuing (yes) vs discontinuation (no). Major independent variable 
hoc dataset was also the source of the background patient characteristics. Costs 
and benefits were discounted at 5% and assessed from the Canadian perspective. 
Sensitivity analyses were performed. RESULTS: Both CANA 100 and 300 mg were 
dominant compared to SAXA 5 mg (lower net cost and greater quality-adjusted 
life-years [QALYs]). CANA 100 and 300 mg reduced costs (–$375 and –$771, respec-
tively) and improved QALYs (0.033 and 0.057, respectively) over 40 years. Sensitivity 
analyses support these findings. CONCLUSIONS: These results suggest that using 
CANA in older individuals is cost-effective versus SAXA in Canada.
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OBJECTIVES: The key challenges in the successful treatment of type 2 diabetes 
include maintaining tight glycemic control, minimizing the risk of hypoglycemia, 
controlling cardiovascular risk factors, and controlling body weight. The aim of the 
present analysis was to evaluate the cost per patient achieving a composite clinical 
endpoint (HbA1c < 7%, with no weight gain and no hypoglycemic events) in patients 
with type 2 diabetes in Canada receiving liraglutide 1.2 mg, liraglutide 1.8 mg, thia-
zolidinedione, sulfonylurea, insulin glargine, sitagliptin or exenatide. METHODS: 
The proportion of patients achieving control was taken from a meta-analysis of the 
phase 3 trial program of liraglutide. Treatment costs were estimated from a health-
care payer perspective. Cost-effectiveness in terms of cost per patient achieving the 
composite endpoint (cost of control) was evaluated with an economic model devel-
oped in Microsoft Excel. No discounting was applied to cost or clinical outcomes as 
these were not projected beyond a 1-year time horizon. Sensitivity analyses were 
performed. RESULTS: Liraglutide 1.8 mg was associated with the lowest number 
needed to treat to bring one patient to the composite endpoint. Evaluation of only 
annual pharmacy costs indicated that was associated with the lowest direct annual 
costs. Combining the clinical efficacy data with the annual cost of medications 
produced cost of control values of CAD 6,070 (liraglutide 1.2 mg), CAD 6,949 (lira-
glutide 1.8 mg), CAD 7,237 (glimepiride), CAD 7,704 (exenatide), CAD 8,297 (insulin 
glargine), CAD 8,741 (pioglitazone) and CAD 9,270 (sitagliptin) per patient achiev-
ing the composite endpoint. CONCLUSIONS: Liraglutide 1.2 mg and 1.8 mg were 
associated with the lowest cost of control values, driven by the high proportion of 
patients achieving the composite endpoint. A relatively low cost of control value 
was achieved for glimepiride, driven by low acquisition costs, despite relatively few 
patients achieving the composite endpoint.
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OBJECTIVES: We determined based on the adquisition cost of the different DPP4 
inhibitors (IDDP4) in Mexico, the cost of daily treatment and performed a cost effec-
tiveness analysis having the percentage of patients with a HbA1c level less than 7% 
calculating the number needed to treat for each treatment (NNT). METHODS: Due 
that there are no head to head studies between IDPP4 therapies and with the goal of 
diminish confounding factors, we performed a search of clinical studies controlled 
with placebo in naïve patients for DPP4 therapies available in Mexico (linagliptin, 
saxagliptin, vildagliptin and sitagliptin) five studies were included. According to the 
American Asociation for the Diabetes 2011, the endpoint was determined as control 
if the patient had a HbA1c less than 7 mg/dL. The follow up time was 24 weeks. NNT 
was calculated for each therapy, in the case of vildagliptin where two studies were 
included, the results were pondered. Using the NNT we calculated the mean cost 
effectiveness ratio. RESULTS: The efficacy measured by the percentage of patients 
that reach a Hb1Ac less than 7 range from 25.3% to 42% in the IDPP4 group and from 
11.6 to 24% in the placebo group. The NNT calculated for each IDDP4 are: sitagliptin 
4.17, vildagliptin 5.48, saxagliptin 7.14 and linagliptin 7.35. The cost effectiveness 
for sitagliptin was 6,885 pesos, vildagliptin 8,503.07 pesos, saxagliptin 11,475 pesos 
and linagliptin 11,891.04 pesos. CONCLUSIONS: Sitagliptin has the less NNT of all 
IDDP4, so it may make a more efficient resource asignation. The mean cost effec-
tiveness ratio help us to interpret the real cost of the treatment analized with the 
same effectiveness measure.
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OBJECTIVES: To evaluate the pharmacoeconomic outcome of GLP-1 receptors ago-
nist vs. DPP-4 inhibitors in patients with type 2 diabetes. METHODS: A systematic 
literature search of pharmacoeconomic studies on GLP-1 receptors agonist vs. 
DPP-4 inhibitor was carried out in following databases: PubMed, Embase, Cochrane 
Library, and Chinese Knowledge Infrastructure (CNKI) (from the inception to 
April.2014). Two review authors independently applied the inclusion criteria, 
assessed trial quality, and extracted the data. The methodological qualities were 
evaluated by a scale of 26 items which developed based on 3 economic evaluation 
principles and guidelines (Drummond’s, Ramsey’s and Papaioannou’s) , and the 
data were analyzed using descriptive analysis. RESULTS: According to the inclu-
sion and exclusion criteria 6 randomized controlled clinical trials and modeling 
studies were selected, including 4 studies of liraglutide+ metformin vs. sitagliptin+ 
metformin, 1 study of exenatide+ metformin vs. sitagliptin + metformin, and 1 
study of exenatide vs. sitagliptin. The methodological quality of them were scored 
19-24(total score was 26). There were 5 CUA studies which conducted a long-term 
simulation ≥ 35 years using CDM model, and 1 short-term CEA study. 4 studies 
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OBJECTIVES: To compare 12-month adherence to liraglutide once daily (QD) or 
exenatide once weekly (QW) between commercially insured patients with type 2 
diabetes mellitus (T2DM) newly initiating liraglutide QD or exenatide QW in the 
U.S. METHODS: This retrospective cohort study used U.S. administrative claims 
data to study patients with T2DM initiating liraglutide QD or exenatide QW (initiated 
therapy= index therapy). Patients were included if they had T2DM, were glucagon-
like peptide-1 receptor agonist (GLP-1RA)–naïve, initiated liraglutide QD or exenatide 
QW from 2/1/2012–10/1/2012 (date of initiation= index), were aged ≥ 18y at index, 
and had continuous enrollment for 12 months before (baseline) to 12 months after 
index (follow-up). The study outcome was index GLP-1RA adherence (proportion 
of days covered [PDC] during follow-up, dichotomized at ≥ 80% versus < 80%, and 
at ≥ 90% versus < 90%). These PDC thresholds have been shown to be predictive of 
reduced hospitalization and mortality for patients with diabetes. Multivariable logis-
tic regressions compared adherence between the GLP-1RAs, adjusting for potential 
confounders. Sensitivity analyses were performed separating liraglutide QD by dose 
(1.2 mg/1.8 mg). RESULTS: Study sample included 10,829 liraglutide QD (4,945 1.2 
mg; 5,884 1.8 mg) patients and 3,173 exenatide QW patients. In each group, mean age 
was approximately 52 years and the proportion of females was 50% for exenatide 
QW and 54% for liraglutide QD. In multivariable-adjusted analyses, liraglutide QD 
patients had statistically significant lower odds of achieving a PDC≥ 80% (odds ratio 
[OR] treating exenatide QW as reference= 0.888, P= .007, 95% confidence interval 
[CI]= 0.816 to 0.968) and statistically significant lower odds of achieving a PDC≥ 90% 
(OR= 0.757, P< .001, 95% CI= 0.690 to 0.831) than exenatide QW patients. In sensitivity 
analyses, results when separating liraglutide QD by dose were directionally consist-
ent. CONCLUSIONS: Patients receiving exenatide QW had greater adjusted odds 
of clinically significant adherence thresholds compared with patients receiving 
liraglutide QD in this retrospective analysis.
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OBJECTIVES: To assess the barriers to treatment adherence on disease manage-
ment of acromegaly from the provider prospective METHODS: A web-based cross-
sectional survey was conducted from August –October, 2014. Healthcare providers 
who had experience in treating acromegaly patients were asked about barriers to 
treatment adherence and influence on the treatment algorithm based on their 
experiences and perspectives. RESULTS: A total of 23 providers (mean age: 56 
years, female: 48%) completed the survey, including physicians (52%), nurses or 
nurse practitioners (43%) and research coordinators (5%). Most worked at academic 
hospitals (78%). Their specialties included endocrinology & metabolism (70%), neu-
roendocrinology (22%) and neurosurgery (8%). Of the providers, 62% had more than 
10 years of experience (range: 5-40 years) treating acromegaly; 75% of them were 
concerned about the barriers to pharmacological treatment adherence. The great-
est concerns were side effects (100%), financial issues (89%), and the therapy being 
too complicated or inconvenient to patients (56%). Seventy percent (5 MDs and 
11 nurses) had encountered patients with symptoms that became worse toward 
the end of an injection cycle, 80% of physicians adjusted the treatment algorithm 
accordingly. Of 9 nurses who had experiences with somatostatin analog (SSA) 
injections, 67% of them raised concerns, of which the most common were side 
effects (e.g., pain, erythema, hematoma), and time loss due to injections. When 
considering the patient’s specific needs, all physicians and nurses with SSA injec-
tion experience (n= 21) would consider offering an oral therapy to patients if it had 
comparable efficacy and safety to the current long acting SSA treatments. The top 
three determinants to drive decisions in acromegaly maintenance therapy were 
clinical guidelines, lower out-of-pocket cost for the patient, and lower total medical 
costs. CONCLUSIONS: Study results indicated that treatment side effects, financial 
issues, and inconvenience were the leading barriers to treatment adherence from 
the healthcare provider perspective.
PDB69
valiDation of PrescriPtion meDication aDherence PreDiction tool 
(rxaPt) to PreDict non-aDherence amonG DiaBetes Patients enrolleD 
in meDicare
Mhatre SK1, Sansgiry S2, Serna O3, Sansgiry SS1
1University of Houston, Houston, TX, USA, 2VA Medical Center, Houston, TX, USA, 3Cigna 
HealthSpring, Houston, TX, USA
OBJECTIVES: Adherence to diabetes medications in the Medicare population is 
low, which can greatly reduce CMS star ratings for managed care organizations 
(MCOs). Proactive identification of patients at risk for future non-adherence can 
provide MCOs with a selective cost-effective approach to implement adherence 
intervention programs. The study aims to develop and validate a risk assessment 
tool (Prescription Medication Adherence Prediction Tool [RxAPT]) to predict non-
adherence to diabetes medications using Medicare claims data. METHODS: Claims 
data from 2012-2013 was used; data from previous year (baseline period) was used 
to predict adherence in the next year (follow-up period). Members 65 years and 
older with diabetes diagnosis, at least one prescription for diabetes medication, no 
insulin prescription, and continuously enrolled for both the years were included 
in the study. Adherence in the follow-up year was the study outcome, defined as 
proportion of days covered (PDC) ≥ 80%. A multiple logistic regression model was 
used to identify the final model using 70% of the data and risk scores were calcu-
lated using significant predictors from the model. The remaining 30% was used for 
cross-validation using split-sample method. Data from 2011-2012 was used to test 
the temporal validity of the tool. RESULTS: Total sample included 7028 patients. 
Seven significant predictors (all from pharmacy claims) were identified and used 
in the tool. Cross-validation statistics were as follows: C-statistics= 0.74, Hosmer-
Lemeshow goodness-of-fit p< 0.05, sensitivity= 0.71, specificity= 0.66, positive predic-
was intervention (yes/no). Other control variables included were demographics, 
physician specialty, health plan, CMS Risk Score, Charlson comorbidity index and 
number of other medications. RESULTS: In total, 186 hypertensive diabetic patients, 
non-adherent to ACE-Is/ARBs (PDC< 0.8) were identified. Among these patients, 29 
patients switched to other drug classes for treating diabetes and hypertension. After 
excluding those who switched, 157 patients were included in the logistic regression 
model with 131 continuing to use ACEI/ARBs and 26 discontinuing the ACEI/ARBs. 
Intervention and comorbidity index were found to be significantly associated with 
medication discontinuation. Patients who received intervention were more likely 
to persist with ACEI/ARBs (OR: 3.56, 95% CI: 1.06-11.86). Patients with higher CCI 
were more likely to discontinue and less likely to persist with ACEI/ARBs (OR: 0.72, 
95% CI: 0.53-0.99). Other covariates were not significantly associated with medica-
tion discontinuation. CONCLUSIONS: The brief pharmacist call was effective in 
preventing medication discontinuation. Future longer term studies are warranted 
to evaluate the effect of such interventions with other adherence outcomes such as 
proportion of days covered (PDC) and clinical outcomes like blood pressure control.
PDB65
DiaBetes eDucation: Patterns anD imPact on meDication aDherence
Noxon V.1, Davis-Ajami M.L.2, Lu K.1, Wu J.1
1University of South Carolina, Columbia, SC, USA, 2Virginia Commonwealth University, 
Richmond, VA, USA
OBJECTIVES: To determine patterns of learning diabetes care and how this impacts 
medication adherence among respondents with diabetes prescribed oral antidia-
betic (OAD) medications. METHODS: The Medical Expenditure Panel Survey (MEPS) 
household component full year consolidated data files (2010-2012) identified diabetes 
respondents (≥ 18 years) who received OAD medications and participated in the MEPS 
Diabetes Care Survey (DCS). Two groups were created from all eligible respondents 
based on how they learned diabetes care: 1) from a single primary care provider or 
medical specialist resource versus 2) multiple resources (medical provider plus inter-
net and/or group classes). OAD medication adherence was measured using the medi-
cation possession ratio (MPR). Respondents with MPR ≥ 0.8 were defined as adherent. 
Logistic regression identified significant socioeconomic factors associated with the 
learning approach (single provider versus multiple resources) used to learn diabetes 
care. RESULTS: A total of 1,347 respondents (58.5%, representing 12.6 million indi-
viduals in the U.S.) and 772 respondents (41.5%, representing 8.9 million individuals 
in the U.S.) learned about diabetes care from single resource and multiple resources 
respectively. Respondents reporting ages younger than 65 years, college degrees, high 
income levels, and treated with diet modification were more likely to learn diabetes 
care from multiple resources. No significant difference in MPR was observed between 
respondents learning diabetes care from a single provider resource (MPR= 0.66) versus 
multiple resources (MPR= 0.64, p= 0.245). Less than 45% of the respondents in both 
groups (single provider resource: 42.6%, multiple resources: 40.2%, p= 0.352) were 
adherent to OAD medications. CONCLUSIONS: Age, income and education levels, 
and whether being treated with diet modification influenced the approach to learning 
about diabetes care. Using medical providers only or multiple resources to learn about 
diabetes care had no impact on the OAD medication adherence.
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OBJECTIVES: To examine the effect of a brief pharmacist telephone intervention on 
adherence to ACE-Is/ARBs among non-adherent hypertensive patients with diabetes 
enrolled in a Texas-based Medicare Advantage plan. METHODS: The health plan 
medical claims data was used to identify patients with hypertension and diabetes 
diagnoses and at least 2 fills for ACE-Is or ARBs between January/2013-October/2013. 
Patients who failed to refill their medication for more than one day, and had a pro-
portion of days covered (PDC) < 0.8 were considered non-adherent and contacted 
by a pharmacist by phone. Descriptive statistics were conducted to assess the fre-
quency distribution of sample demographic characteristics at baseline. A multiple 
linear regression was conducted to assess the intervention effect on adherence 
during the 6 months post-intervention. The outcome variable was 6-month post 
intervention PDC. Other control variables included were baseline PDC, demograph-
ics, physician specialty (primary care vs. specialist), health plan (low income subsidy 
vs. not), CMS Risk Score, Charlson comorbidity index and number of other medica-
tions. RESULTS: A total of 131 patients were included in the analysis with 66 in the 
intervention group. The mean post intervention PDC for the intervention group was 
0.58 (SD±0.26) and 0.29 (SD±0.17) for the control group. Intervention was a significant 
predictor of better adherence in the linear regression model after adjusting for all 
the other baseline covariates (β = 0.318, p< 0.001), but the post intervention PDC was 
still lower than the generally accepted PDC of 0.8. Other covariates were not sta-
tistically significant. CONCLUSIONS: The brief pharmacist telephone intervention 
resulted in significantly better PDCs during the 6 months following the intervention 
but the overall PDC rates in both the intervention and control groups remained low. 
Future research should investigate the impact of behavior modifications which 
incorporate motivational interviewing and determine if this leads to a sustainable 
behavioral change and improved adherence.
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